Cutler Group’s AstraZeneca AZN Stock Holding History

Cutler Group’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-21,500	Closed	-$24K	–	3602
2023 Q3	$24K	Buy	+21,500	New	+$2.94M	﹤0.01%	1897
2023 Q1	–	Sell	-11,100	Closed	-$1K	–	3783
2022 Q4	$1K	Sell	11,100 -650	-6%	-$81.5K	﹤0.01%	3904
2022 Q3	$69K	Sell	11,750 -2,650	-18%	-$336K	﹤0.01%	1657
2022 Q2	$37K	Sell	14,400 -9,700	-40%	-$1.27M	﹤0.01%	2169
2022 Q1	$38K	Buy	24,100 +13,100	+119%	+$1.57M	﹤0.01%	2476
2021 Q4	$39K	Hold	11,000	–	–	﹤0.01%	2589
2021 Q3	$50K	Buy	11,000 +2,000	+22%	+$233K	﹤0.01%	2504
2021 Q2	$35K	Buy	+9,000	New	+$987K	﹤0.01%	2786
2018 Q3	–	Sell	-3,400	Closed	-$3K	–	4076
2018 Q2	$3K	Hold	3,400	–	–	﹤0.01%	3353
2018 Q1	$6K	Hold	3,400	–	–	﹤0.01%	3138
2017 Q4	$10K	Sell	3,400 -5,250	-61%	-$354K	﹤0.01%	3102
2017 Q3	$17K	Buy	8,650 +4,950	+134%	+$313K	﹤0.01%	3260
2017 Q2	$17K	Buy	+3,700	New	+$242K	﹤0.01%	3569

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Cutler Group's AZN Position: Q4 2023 in Review

Cutler Group sold out of AstraZeneca (AZN) in Q4 2023, closing a stake of 5,369 shares — an estimated $698K sold.

Cutler Group first reported a position in AZN in Q4 2015 and held it in 21 quarters. The position peaked at $727K in Q3 2023. 1,130 funds tracked by Wall St. Rank hold AZN as of Q4 2023.

Cutler Group reported no remaining AstraZeneca position as of Q4 2023 after selling out during the quarter.
Cutler Group sold 5,369 AstraZeneca shares in Q4 2023, an estimated $698K.
Cutler Group first reported a position in AstraZeneca in Q4 2015 and held it in 21 quarters.
Cutler Group's AstraZeneca position peaked at $727K in Q3 2023.
1,130 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.